Three grams of glycine taken before bed produces a measurable drop in core body temperature and a shift in sleep architecture toward deeper slow-wave sleep — effects confirmed in polysomnography studies in humans. What makes this remarkable is the mechanism: glycine is simultaneously the simplest amino acid in biology and one of the few molecules that acts as an obligatory co-agonist at the NMDA receptor. Its sleep-promoting effects depend not on sedation, but on its ability to engage thermoregulatory circuits in the suprachiasmatic nucleus.
What Is Glycine?
Glycine is the smallest proteinogenic amino acid, consisting of a single hydrogen atom as its side chain. Despite this structural simplicity, it plays multiple, non-overlapping roles in the central nervous system. In the spinal cord and brainstem, glycine functions as a major inhibitory neurotransmitter via strychnine-sensitive glycine receptors (GlyRs). In the forebrain — and critically, in the suprachiasmatic nucleus (SCN) — it serves as an obligatory co-agonist at the N-methyl-D-aspartate (NMDA) glutamate receptor, binding to a distinct site from glutamate itself.[1]
This dual identity is the key to understanding why exogenous glycine produces effects that look paradoxical on the surface: it is both inhibitory and excitatory, depending on receptor subtype and anatomical location.
How Glycine Works at the NMDA Receptor
Obligatory Co-Agonism: The NMDA receptor cannot open in response to glutamate alone. It requires simultaneous binding of a co-agonist — either glycine or D-serine — at the GluN1 subunit’s glycine-binding site. Without co-agonist occupancy, the channel remains closed even when glutamate is bound. This makes glycine availability a rate-limiting factor for NMDA receptor activity in regions where extracellular glycine concentrations are not saturating.[1]
SCN Activation and Thermoregulation: Oral glycine crosses the blood-brain barrier via the ASCT1 transporter and elevates extracellular glycine in brain regions including the SCN. Rat studies using microdialysis have demonstrated that exogenous glycine activates NMDA receptors specifically within the SCN, which in turn signals peripheral vasodilation through descending autonomic pathways. The result is increased cutaneous blood flow at the extremities and accelerated heat dissipation.[2]
Core Body Temperature Drop: A drop in core body temperature is one of the most reliable physiological triggers for sleep onset and slow-wave sleep consolidation. Endogenous circadian temperature decline begins in the late evening and reaches its nadir in the early morning. Glycine appears to potentiate this natural process by amplifying SCN-mediated vasodilation, effectively accelerating the thermal phase of sleep initiation.[2]
Brainstem Inhibition: Separately, glycine acting at spinal and brainstem GlyRs contributes to motor inhibition during REM sleep and may modulate arousal thresholds. While oral glycine’s contribution to this pool is less well characterized than its NMDA effects, the inhibitory action is mechanistically consistent with reduced sleep fragmentation.[3]
Clinical Evidence
Subjective Sleep Quality: In a placebo-controlled crossover trial conducted by Yamadera and colleagues, healthy adults with mild, ongoing sleep complaints took 3 g of glycine or placebo before bed. The glycine condition produced significant improvements in subjective sleep quality, reduced fatigue on waking, and improved next-day clear-headedness as measured by validated questionnaires.[4]
Polysomnographic Findings: A follow-up study by Bannai and Kawai used polysomnography to characterize what 3 g of pre-sleep glycine actually did to sleep architecture. The findings were specific and interpretable: shortened latency to sleep onset, shortened latency to slow-wave sleep, and a stable or increased proportion of SWS without suppression of REM. This profile is distinct from benzodiazepines or Z-drugs, which typically suppress SWS.[3]
Daytime Performance After Sleep Restriction: In a study examining partial sleep restriction, glycine ingestion before bed mitigated next-day decrements in psychomotor performance and subjective fatigue compared to placebo. This is consistent with glycine improving sleep efficiency rather than merely sleep duration.[5]
Temperature Measurements: In animal models, oral glycine administration produced reproducible drops in core body temperature alongside increases in cutaneous blood flow — directly confirming the vasodilation-mediated thermoregulatory mechanism proposed from human sleep data.[2]
Safety Profile
Glycine has one of the most favorable safety profiles of any sleep-modulating compound. As a non-essential amino acid synthesized endogenously and present in the normal diet (collagen, meat, legumes), it is recognized as Generally Recognized as Safe (GRAS) by the FDA at typical supplemental doses. Studies using 3 g nightly have reported no significant adverse events, no morning grogginess, and no withdrawal phenomena.
Doses up to 9 g daily have been used in clinical research without serious safety signals, though gastrointestinal discomfort and mild nausea can occur at higher doses. Because glycine is an NMDA co-agonist, theoretical caution is warranted in patients with active psychotic disorders, where NMDA hypofunction is implicated and the directionality of effects from exogenous co-agonist loading is not fully established. Patients on clozapine or other agents that interact with the glycine site should consult a clinician.
Glycine does not produce sedation in the traditional pharmacological sense — it does not impair driving performance, does not potentiate alcohol, and does not affect sleep architecture in ways that resemble GABAergic hypnotics. The mechanism is fundamentally thermoregulatory rather than sedating.
Glycine vs Other Sleep Approaches
vs Melatonin: Melatonin acts primarily as a chronobiotic, shifting the circadian phase via MT1/MT2 receptors in the SCN. Glycine acts on a parallel but distinct SCN pathway — NMDA-mediated thermoregulation — and does not appear to phase-shift the circadian clock. The two are mechanistically complementary rather than redundant.
vs Benzodiazepines and Z-Drugs: GABA-A positive allosteric modulators (zolpidem, eszopiclone, benzodiazepines) reliably induce sleep but suppress slow-wave sleep and REM in ways that compromise sleep’s restorative function. Glycine, by contrast, preserves or enhances SWS and does not suppress REM, making it more aligned with physiological sleep.[3]
vs Magnesium and L-Theanine: Both magnesium and L-theanine modulate sleep through NMDA-related mechanisms (magnesium as a voltage-dependent channel blocker, theanine as a glutamate modulator). Glycine’s mechanism — co-agonist binding at GluN1 — is distinct and acts upstream of the channel-gating step that magnesium influences. There is no clinical reason these approaches cannot be combined, and the mechanistic divergence suggests potential additive effects.
vs Thermal Interventions: Warm baths and warm-water foot soaks before bed produce the same downstream effect glycine achieves pharmacologically: peripheral vasodilation and accelerated heat loss. The convergence of behavioral and pharmacological thermoregulation on the same sleep-onset mechanism is itself strong evidence for the centrality of this pathway.
Practical Considerations
The clinical evidence converges on 3 g of glycine taken 30–60 minutes before bed as the most studied and best-characterized dose. Glycine has a mild sweet taste and dissolves readily in water, which is the typical administration route in trials. Because the mechanism depends on SCN activation and peripheral vasodilation, glycine’s effects are most pronounced in individuals who have difficulty with sleep onset or who exhibit attenuated nocturnal temperature decline — a pattern common in older adults and shift workers.
Glycine is not a hypnotic and should not be expected to override significant insomnia driven by anxiety, pain, or circadian misalignment. Its effect size in healthy adults with mild sleep complaints is modest but consistent, and the favorable safety profile makes it a reasonable first-line strategy before pharmacological hypnotics are considered.
References
- Johnson JW, Ascher P. “Glycine potentiates the NMDA response in cultured mouse brain neurons.” Nature. 1987;325(6104):529-531.
- Kawai N, Sakai N, Okuro M, et al. “The sleep-promoting and hypothermic effects of glycine are mediated by NMDA receptors in the suprachiasmatic nucleus.” Neuropsychopharmacology. 2015;40(6):1405-1416.
- Bannai M, Kawai N. “New therapeutic strategy for amino acid medicine: glycine improves the quality of sleep.” Journal of Pharmacological Sciences. 2012;118(2):145-148.
- Yamadera W, Inagawa K, Chiba S, et al. “Glycine ingestion improves subjective sleep quality in human volunteers, correlating with polysomnographic changes.” Sleep and Biological Rhythms. 2007;5(2):126-131.
- Bannai M, Kawai N, Ono K, et al. “The effects of glycine on subjective daytime performance in partially sleep-restricted healthy volunteers.” Frontiers in Neurology. 2012;3:61.
